Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.

GeneCradle Inc

5 clinical trials · 5 recruiting · INDUSTRY

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

Trials by GeneCradle Inc

RECRUITINGPhase 1NCT05860569

Safety Evaluation of Gene Therapy Drug in the Treatment of Primary Hypertriglyceridemic Patients With Recurrent...

The study will evaluate safety and tolerance of intravenous delivery of GC304 gene therapy drug as a treatment of primary hypertriglyceridemic patients with previous onset of...

Sponsor: GeneCradle IncEnrolling: 71 location
Hypertriglyceridemia, Familial
RECRUITINGPhase 1 / Phase 2NCT06421831

Evaluation of Safety and Efficacy of Gene Therapy Drug in the Treatment of Spinal Muscular Atrophy (SMA) Type 3 Patients

The study will evaluate safety and efficacy of intrathecal delivery of GC101 gene therapy drug as a treatment of spinal muscular atrophy Type 3 (SMA 3) patients.

Sponsor: GeneCradle IncEnrolling: 211 location
Spinal Muscular Atrophy Type 3
RECRUITINGPhase 1 / Phase 2NCT05824169

Evaluation of Safety and Efficacy of Gene Therapy Drug in the Treatment of Spinal Muscular Atrophy (SMA) Type 1 Patients

The study will evaluate safety and efficacy of intrathecal delivery of GC101 gene therapy drug as a treatment of spinal muscular atrophy Type 1 (SMA 1) patients.

Sponsor: GeneCradle IncEnrolling: 184 locations
Spinal Muscular Atrophy
RECRUITINGPhase 3NCT06971094

Safety and Efficacy Evaluation of GC101 Gene Therapy Via Intrathecal (IT) Injectionin the Treatment of Patients With...

This trial employs a multicenter, randomized, open-label, standard-of-care-controlled design and plans to enroll 50 patients with Type 2 SMA aged 2 to 12 years who have previously...

Sponsor: GeneCradle IncEnrolling: 507 locations
SMA - Spinal Muscular Atrophy
RECRUITINGPhase 1 / Phase 2NCT06391736

Evaluation of the Safety and Efficacy of Late-onset Pompe Disease Gene Therapy Drug

This study is being conducted to evaluate the safety and effectiveness of GC301 adeno-associated virus vector expressing codon-optimized human acid alpha-glucosidase (GAA) as...

Sponsor: GeneCradle IncEnrolling: 331 location
Pompe Disease (Late-onset)